While maintaining its 'neutral' position on Ipsen, UBS adjusts its price target from 104 to 108 euros, a new target slightly above the French pharmaceutical company's share price.

'We like the structure of the Albireo deal and its strategic rationale, but our forecasts for Bylvay are well below both consensus and Ipsen's estimated peak sales', the broker says in the summary of its note.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.